Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery
Status:
COMPLETED
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if bromfenac ophthalmic solution can prevent cystoid macular edema (CME) and reduce macular thickness in patients undergoing phacoemulsification surgery for cataract removal. The main questions it aims to answer are:
Does bromfenac reduce the incidence of CME after cataract surgery? Does bromfenac effectively control macular thickness postoperatively compared to standard care? investigators will compare the effects of bromfenac ophthalmic solution to a control group receiving standard postoperative treatment to see if bromfenac provides additional benefits.
Participants will:
Use bromfenac ophthalmic solution as prescribed postoperatively. Attend follow-up visits for macular thickness measurements and assessments of eye health.
Undergo routine postoperative evaluations to monitor for adverse effects.